Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 crossover study of NMD670 in adults with type 3 spinal muscular atrophy
2022-002301-24Phase 2Active
- Sponsor
- NMD Pharma
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ignaseclant in Spinal muscular atrophy type 3 (SMA3) (2 arms), sponsored by NMD Pharma. Primary endpoint: Change from baseline in 6-minute walk test distance after 21-day dosing. Started Jan 2023; status: active.
02
Drugs
ignaseclant
03
Conditions
Spinal muscular atrophy type 3 (SMA3)
Beyond the preview
Go deeper on 2022-002301-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002301-24.